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Plasma metanephrines in renal failure.
Background. Diagnosis of pheochromocytoma in renal fail-
ure poses a diagnostic dilemma due to lack of reliability of
conventional urinary measurements of catecholamine excess.
Measurements of the plasma metanephrines, normetanephrine
and metanephrine (the O-methylated metabolites of nore-
pinephrine and epinephrine), provide an alternative diagnostic
test. The metanephrines may be measured as free metabolites or
after a deconjugation step where measurements reflect mainly
sulfate-conjugated metabolites. The influence of renal insuffi-
ciency states on these various measurements is unclear.
Methods. Plasma free and deconjugated metanephrines and
catecholamines in 17 patients on dialysis with end-stage renal
disease and 19 patients with renal insufficiency (creatinine clear-
ance, 5–78 mL/min) were compared with levels in 89 hyper-
tensives, 68 healthy normotensives, and 51 patients with von
Hippel-Lindau syndrome.
Results. Patients with renal failure had up to two-fold
higher plasma concentrations of catecholamines and free
metanephrines, and more than 12-fold higher plasma concentra-
tions of deconjugated metanephrines than comparison groups.
Plasma free metanephrines and catecholamines were, respec-
tively, within the 95% confidence intervals of reference groups
in 75% and 42% of the dialysis patients, and in 74% and 68%
of patients with renal insufficiency. In contrast, no dialysis pa-
tient and only half the renal insufficiency patients had plasma
levels of deconjugated metanephrines within the reference in-
tervals. Plasma levels of deconjugated metanephrines, but not
free metanephrines, showed strong inverse relationships with
creatinine clearance.
Conclusion. Plasma concentrations of free metanephrines
are relatively independent of renal function and are, therefore,
more suitable for diagnosis of pheochromocytoma among pa-
tients with renal failure than measurements of deconjugated
metanephrines.
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The metanephrines, normetanephrine and meta-
nephrine, are produced by O-methylation of the cate-
cholamines, norepinephrine and epinephrine [1] (Fig. 1).
Further metabolism occurs by deamination or sul-
fate conjugation. Adrenal medullary chromaffin cells
represent the largest single tissue source of circulat-
ing metanephrines, accounting for more than 91% of
metanephrine and 26% to 40% of normetanephrine [2,
3]. Production of these metabolites within chromaffin
cells is continuous and independent of variations in cat-
echolamine release [4], explaining why measurements
of these metabolites provide more superior markers for
diagnosis of pheochromocytoma than the parent cate-
cholamines [5–8].
Metanephrines in plasma can be measured as the free
metabolites or after a deconjugation step that converts
the sulfate conjugates to the free metabolites. Although
only fractions of the free metanephrines are metabolized
to sulfate conjugates (most are deaminated), plasma lev-
els of the conjugates are normally 20- to 30-fold higher
than levels of the free metabolites [2]. This difference ap-
pears to largely reflect different clearance mechanisms.
The free metanephrines are rapidly cleared from the cir-
culation by active uptake mechanisms operative through-
out different cells and tissues of the body, while clearance
of the sulfate-conjugates is slower and dependent on elim-
ination in urine [3, 4].
Suspicion of pheochromocytoma among patients with
impaired renal function is most usually based on the pres-
ence of typical symptoms, hypertension or hemodynamic
instability. Diagnosis of the tumor in such patients can be
troublesome due to influences of impaired renal function
on elimination of catecholamines and their metabolites
in urine, often making conventional urinary tests of cate-
cholamine excess unreliable. Plasma measurements may
also be compromised by increased sympathetic outflow or
dependence of catecholamine metabolite levels on clear-
ance by the kidneys [9, 10]. These problems are particu-
larly acute in end-stage renal disease (ESRD), when pa-
tients are functionally anephric and on dialysis [11]. There
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Fig. 1. Diagram showing the main pathways for metabolism of the
norepinephrine and epinephrine derived from sympathoneuronal
or adrenalmedullary sources. Deamination in sympathetic nerves
(white) is the major pathway of catecholamine metabolism and in-
volves intraneuronal deamination of norepinephrine leaking from
storage granules, or of norepinephrine recaptured after release by
sympathetic nerves. Metabolism in adrenal chromaffin cells (black)
involves O-methylation of catecholamines leaking from storage gran-
ules into the cytoplasm of adrenalmedullary cells. The extraneu-
ronal pathway (gray) is a relatively minor pathway of metabolism
of catecholamines released from sympathetic nerves or the adrenal
medulla, but is important for further processing of metabolites pro-
duced in sympathetic nerves and adrenal chromaffin cells. The free
metanephrines produced in extraneuronal tissues or adrenal chromaffin
cells are either further metabolized by deamination or sulfate conjuga-
tion. Abbreviations: NE, norepinephrine; E, epinephrine; DHPG, 3,4-
dihydroxyphenylglycol; MN, metanephrine; NMN, normetanephrine;
MHPG, 3-methoxy-4-hydroxyphenylglycol; VMA, vanillylmandelic
acid; MHPG-SO4, 3-methoxy-4-hydroxyphenylglycol sulfate; NMN-
SO4, normetanephrine-sulfate; MN-SO4, metanephrine-sulfate; MAO,
monoamine oxidase; COMT, catechol-O-methyltransferase; ADH, al-
cohol dehydrogenase; SULT1A3, phenolsulfotransferase type 1A3.
may also be concerns about influences of renal function
on some urinary measures of catecholamine excess in pa-
tients with milder forms of renal insufficiency [12, 13].
The presence of pheochromocytoma in hypertensive
patients, with or without renal failure, is rare, but should
be considered when associated with symptoms of cate-
cholamine excess, or when hypertension is unresponsive
to therapy. The risk of pheochromocytoma is higher in
several hereditary conditions. Von Hippel-Lindau (VHL)
syndrome is one example where there is a high risk of
both pheochromocytoma and kidney cancer, and where
the former tumor may often need to be considered in the
setting of mildly to severely impaired renal function [5].
This study examined the influence of mildly to severely
impaired renal function on plasma concentrations of cat-
echolamines and free and deconjugated metanephrines.
Because the circulatory clearance of free metanephrines
is largely independent of renal function, we hypothesized
that plasma concentrations of these metabolites, unlike
the conjugated metabolites, would remain largely unin-
fluenced by renal insufficiency states.
METHODS
Subjects
Patients included 17 with ESRD (renal failure patients)
who were on hemodialysis (N = 16) or peritoneal dial-
ysis (N = 1), and 19 patients with milder impairments
of renal function (renal insufficiency) who were not on
dialysis (Table 1). These patients were from two sources:
(1) 24 patients presenting to the Department of Nephrol-
ogy at St. Radboud University Medical Center for clin-
ical examination of renal insufficiency, dialysis therapy,
or consideration for a kidney transplant; and (2) 12 pa-
tients screened for pheochromocytoma at the National
Institutes of Health (NIH).
ESRD in the 17 patients on dialysis was secondary to
hypertension (N = 3), diabetes mellitus with or without
hypertension (N = 4), chronic interstitial renal disease
(N = 2), Alport’s syndrome (N = 2), focal glomeru-
losclerosis (N = 2), and bilateral nephrectomies due
to renal cell carcinoma in VHL patients (N = 4). Im-
paired renal function among the 19 patients with renal
insufficiency was due to renal artery stenosis (N = 8),
unilateral nephrectomies and renal tumors or cysts in re-
maining kidneys due to VHL syndrome (N = 8), chronic
or IgA glomerulonephritis (N = 2), and polycystic kid-
ney disease (N = 1). The mean (± SD) creatinine clear-
ance among patients with renal insufficiency was 49 ± 21
mL/min, with a range from 5 to 78 mL/min. These pa-
tients included four with ESRD (clearance <25 mL/min)
who were not on dialysis.
Comparison groups included 68 healthy normotensive
subjects, 89 patients with primary hypertension, and 51
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Table 1. Patient characteristics
Renal Renal Essential Normotensive VHL
failure (dialysis) insufficiency hypertension volunteers syndrome
N 17 19 89 68 51
Age mean ± SD 54 ± 19 51 ± 13 49 ± 13 48 ± 8 47 ± 8
Male/Female 14/3 8/11 40/49 37/31 21/30
patients with the VHL syndrome undergoing routine
screening for pheochromocytoma (Table 1).
Pheochromocytoma in patients screened for the tu-
mor was excluded according to previously reported cri-
teria [7]. All patients with impaired renal function and
many of the hypertensives and patients with VHL syn-
drome were on medications, which, in patients with im-
paired renal function or hypertension, included calcium
channel antagonists, ACE-inhibitors, diuretics, and beta-
adrenoceptor blockers. Procedures were approved by the
appropriate institutional review boards, and all partici-
pants gave written informed consent.
Collection of blood and urine samples
Blood samples were obtained from all patients us-
ing an indwelling intravenous catheter inserted into an
antecubital vein with patients in the supine position
for at least 20 minutes before blood collections. Blood
samples were collected after avoidance of medications
containing acetaminophen, which, in our liquid chro-
matographic method of analysis, interferes with mea-
surements of normetanephrine [14]. In the patients on
dialysis, blood samples were drawn immediately before
the next dialysis. Samples of blood were transferred into
tubes containing heparin as anticoagulant or EGTA and
glutathione and immediately placed on ice until cen-
trifuged (4◦C) to separate the plasma. Plasma samples
were stored at −80◦C until assayed. Twenty-four–hour
urine specimens were collected in patients with renal in-
sufficiency or VHL syndrome into containers containing
30 mL of 6 M hydrochloric acid as a preservative.
Plasma and urinary catecholamines and metanephrines
Plasma concentrations of catecholamines (nore-
pinephrine and epinephrine) were quantified by liq-
uid chromatography with electrochemical detection
[15]. Plasma concentrations of free metanephrines
(normetanephrine and metanephrine) were determined
using a different liquid chromatography procedure after
extraction onto solid-phase ion exchange columns [14].
Plasma concentrations of deconjugated metanephrines
were determined by the same method after a one-hour
incubation (37◦C) of 200 lL of plasma with 0.33 units of
sulfatase (Sigma, St Louis, MO, USA). Intra-assay coef-
ficients of variation were 1.9% for norepinephrine, 3.0%
for epinephrine, 4.2% for normetanephrine, and 3.3% for
metanephrine. Interassay coefficients of variation were
3.2% for norepinephrine, 9.9% for epinephrine, 7.1% for
normetanephrine, and 5.1% for metanephrine.
Twenty-four–hour urinary excretion of fraction-
ated metanephrines (separately measured deconjugated
normetanephrine and metanephrine) in 12 patients with
renal insufficiency and the VHL patients was determined
by liquid chromatography with electrochemical detection
[16].
Data analysis
As described elsewhere [17], logarithmic trans-
formations are required to obtain normal distribu-
tions for plasma concentrations of catecholamines and
metanephrines. Therefore, data are presented as geo-
metric means with 95% confidence intervals calculated
from the antilogarithm of the mean ± 2 SD of the trans-
formed data. Upper reference limits for plasma con-
centrations of catecholamines and free or deconjugated
metanephrines were determined from the 95% confi-
dence intervals for the combined data from the three ref-
erence groups. Plasma concentrations of catecholamines
in patients with impaired renal function were defined as
normal if both norepinephrine and epinephrine were be-
low the upper limit of the 95% confidence intervals in the
three reference groups. Similarly, plasma free or decon-
jugated metanephrines in patients with impaired renal
function were defined as normal if both normetanephrine
and metanephrine were below the upper limit of 95%
confidence intervals in the three reference groups.
Creatinine clearance was calculated by dividing the 24-
hour urinary output of creatinine by the serum concen-
tration of creatinine. Similar to calculations of creatinine
clearances, clearances of deconjugated normetanephrine
and metanephrine (representing almost exclusively the
conjugated metabolites) were calculated by dividing
the 24-hour urinary output of normetanephrine and
metanephrine by the respective plasma concentrations
of deconjugated normetanephrine and metanephrine.
Differences in plasma or urinary catecholamines and
free or deconjugated metanephrines among groups were
assessed using analysis of variance (ANOVA) carried out
on logarithmically transformed data, with post-hoc tests
of significance determined using Scheffe’s method. Sim-
ilarly, significances of relationships between creatinine
clearances and plasma concentrations of catecholamines
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Table 2. Plasma concentrations of free and deconjugated normetanephrine (NMN) and metanephrine (MN) and free norepinephrine and
epinephrine in patients with renal failure or renal insufficiency compared to hypertensive, normotensive, and VHL comparison groups
Renal Renal Essential Normotensive VHL
failure (dialysis) insufficiency hypertension volunteers syndrome
Free NMN 96b,c,d 82b,c,d 60 47 59
(26–410) (29–307) (24–148) (18–119) (26–137)
Free MN 41d 34 28 30 23
(8–130) (1–142) (11–71) (13–67) (8–64)
Deconjugated NMN 31,477a,b,c,d 5272b,c,d 2109c 1521 2449c
(7,225–101,082) (1,519–16,949) (783–5,675) (669–3,451) (988–6067)
Deconjugated MN 14,355a,b,c,d 2,089b,c,d 809 822 889
(8,266–41,469) (409–9286) (324–2023) (346–1954) (326–2427)
Norepinephrine 417b,c,d 396c,d 268c 195 246
(122–2738) (88–1131) (101–708) (80–475) (101–601)
Epinephrine 56b,c,d 21 21 18 13
(5–422) (2–181) (4–124) (3–77) (2–97)
Data are shown as geometric mean values (pg/mL) with 95% confidence intervals in parentheses.
aP < 0.001 higher than in renal insufficiency.
bP < 0.05 higher than in essential hypertension.
cP < 0.05 higher than in normal volunteers.
dP < 0.05 higher than in VHL syndrome.
and free or deconjugated metanephrines were deter-
mined using Pearson’s correlation coefficient, deter-
mined using logarithmically transformed values for cat-
echolamines and metanephrines. Chi-square tests were
used to determine differences in proportions of normal
and abnormal results for plasma catecholamines, free
metanephrines, and deconjugated metanephrines.
RESULTS
Mean plasma concentrations of free normetanephrine
were up to two-fold higher in patients with ESRD on dial-
ysis (P < 0.002) or milder renal insufficiency (P < 0.03)
than in groups of normotensive volunteers, essential hy-
pertensives, and patients with VHL syndrome (Table 2).
Plasma concentrations of free metanephrine showed lit-
tle differences among groups, but were higher (P < 0.01)
in patients on dialysis compared to those with VHL syn-
drome. In contrast to the free metanephrines, plasma
concentrations of deconjugated metanephrines in both
groups of patients with impaired renal function were con-
sistently and significantly (P < 0.0001) higher than levels
in all three reference groups. Plasma concentrations of
deconjugated metanephrines were particularly elevated
in patients on dialysis. In these patients, mean plasma con-
centrations of deconjugated metanephrines were more
than 12-fold higher than concentrations in the three ref-
erence groups, and more than eight-fold higher than those
in patients with milder renal insufficiency states. Similar
to plasma free metanephrines, mean plasma concentra-
tions of norepinephrine and epinephrine were also up to
two-fold higher (P < 0.04) in patients on dialysis than in
the three reference groups. Higher plasma levels of nore-
pinephrine were also present in patients with milder re-
nal insufficiency compared to normotensives (P < 0.0001)
and VHL patients (P < 0.03), whereas epinephrine levels
were not significantly different between groups.
Plasma levels of deconjugated metanephrines were up
to 350-fold higher than free metanephrines and, thus,
much easier to measure in patients with impaired re-
nal function than levels of free metanephrines or cate-
cholamines. Difficulties with measurements of the much
lower plasma concentrations of free metanephrines and
catecholamines in patients with impaired renal func-
tion were compounded by interferences from unknown
plasma contaminants during liquid chromatographic
analysis of plasma samples. This was particularly prob-
lematic for patients on dialysis, where chromatograms
were highly complex with multitudes of additional peaks,
suggesting a build-up of multiple contaminants secondary
to impaired urinary excretion. The complex nature of
chromatograms often necessitated repeated analysis and
always required careful inspection and interpretation of
chromatograms to avoid erroneously elevated results.
Even so, plasma concentrations of free normetanephrine
or metanephrine or both could not be reliably measured
in five out of the 17 (29%) patients on dialysis compared
to none of the patients with milder renal insufficiency, and
only one out of the 208 patients in the other three groups.
Similarly, plasma concentrations of catecholamines could
not be reliably measured in five out of the 17 (29%) pa-
tients on dialysis compared to no patients with milder
renal insufficiency, and only two out of the 208 patients
in the three other groups.
Examination of individual plasma levels of cate-
cholamines and metanephrines in dialysis and renal in-
sufficiency patients compared to normotensives, essen-
tial hypertensives, and VHL patients further illustrated
the relatively mild effects of impaired renal function on
plasma levels of catecholamines and free metanephrines
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Fig. 2. Plasma concentrations of cat-
echolamines, free metanephrines, and
deconjugated metanephrines in individual
patients with ESRD on dialysis () and
patients with milder renal insufficiency (∆)
compared to individual values in the three
reference groups. Horizontal dashed lines
represent the upper limits of the 95% con-
fidence intervals for values in the reference
population.
compared to the more dramatic effects on deconjugated
metanephrines (Fig. 2). Plasma concentrations of nore-
pinephrine were increased above the upper limit of the
95% confidence intervals in the reference groups (619 pg/
mL) in 28% (10/36) of all patients with impaired renal
function, and plasma concentrations of epinephrine were
increased above the 95% confidence intervals (104 pg/
mL) in 26% (8/31) of patients where these measure-
ments were possible. Plasma concentrations of free
normetanephrine were increased above the upper limit
of the 95% confidence intervals (139 pg/mL) in 16%
(5/32) of all patients with impaired renal function, and
plasma concentrations of metanephrine were increased
above the 95% confidence intervals (70 pg/mL) in 22%
(7/32) of patients where these measurements were possi-
ble. In contrast, plasma concentrations of deconjugated
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normetanephrine or deconjugated metanephrine were
each increased above their respective upper limits (5272
and 2089 pg/mL) in 72% (26/36) of patients with impaired
renal function.
Plasma norepinephrine and epinephrine were normal
in 68% (13/19) of patients with renal insufficiency, and
42% (5/12) of the patients on dialysis in whom both
analytes were measurable. This compares with plasma
free normetanephrine and metanephrine, which were
normal in 74% (14/19) of patients with renal insuffi-
ciency and in 75% (9/12) of the patients on dialysis in
whom both analytes were measurable. In contrast, plasma
concentrations of deconjugated normetanephrine and
metanephrine were normal in only 53% (10/19) of pa-
tients with renal insufficiency and none (0/17) of the pa-
tients on dialysis.
Numbers of normal results for plasma free meta-
nephrines were significantly (P < 0.001) higher than num-
bers of normal results for deconjugated metanephrines
in patients with ESRD on dialysis and for combined
groups of ESRD and renal insufficiency patients. Num-
bers of normal results for plasma catecholamines were
also significantly (P < 0.02) higher than numbers of nor-
mal results for plasma deconjugated metanephrines in
the combined group of ESRD and renal insufficiency pa-
tients. There were no significant differences in numbers of
normal results between plasma catecholamines and free
metanephrines.
Among the patients with VHL syndrome or renal in-
sufficiency there were relatively weak inverse relation-
ships between creatinine clearances and plasma concen-
trations of norepinephrine (r = 0.38, P = 0.001) and
free normetanephrine (r = 0.27, P = 0.02), but no rela-
tionships with plasma epinephrine or free metanephrine
(Fig. 3). In contrast to the weak relationships with plasma
free metanephrines, much stronger inverse relationships
were present between creatinine clearances and plasma
concentrations of deconjugated normetanephrine (r =
0.63, P < 0.0001) and metanephrine (r = 0.59, P < 0.0001).
Urinary excretions (mean ± SD) of deconjugated
normetanephrine were 246 ± 107 lg/day in the patients
with renal insufficiency and 281 ± 133 lg/day in the VHL
group. Urinary excretions of deconjugated metanephrine
were 142 ± 51 lg/day in the patients with renal insuf-
ficiency and 85 ± 80 lg/day in the VHL group. Mean
± SD clearances of creatinine, normetanephrine, and
metanephrine were 49 ± 21 mL/min, 36 ± 10 mL/min,
and 37 mL/min in patients with renal insufficiency, and
110 ± 34 mL/min, 75 mL/min, and 60 ± 21 mL/min in
VHL patients. Among these patients, there were strong
positive relationships between the clearances of creati-
nine with clearances of deconjugated normetanephrine
(r = 0.81, P < 0.001) and metanephrine (r = 0.78, P <
0.001) (Fig. 4).
DISCUSSION
The present study establishes that measurements of
plasma free metanephrines are more suitable than mea-
surements of plasma deconjugated metanephrines for
diagnosis of pheochromocytoma among patients with im-
paired renal function. This conclusion is based on the
finding that among all patients with impaired renal func-
tion, plasma concentrations of free metanephrines were
much less frequently elevated above the upper reference
limits compared to plasma-deconjugated metanephrines.
In particular, only one out of four patients on dialy-
sis showed increased plasma free metanephrines, while
all showed substantially increased plasma concentra-
tions of deconjugated metanephrines, and more than
one out of two patients had increased plasma concentra-
tions of catecholamines. Plasma concentrations of free
metanephrines, therefore, seem to be least dependent
on renal function compared to plasma deconjugated
metanephrines or plasma catecholamines. This conclu-
sion is supported by the strong inverse relationships be-
tween creatinine clearance and plasma concentrations
of deconjugated metanephrines, the weaker relation-
ships between creatinine clearance and plasma cate-
cholamines, and the even weaker relationships between
creatinine clearance and plasma free metanephrines.
The important contributions of renal elimination to the
circulatory clearance and resulting plasma concentra-
tions of deconjugated metanephrines are further sup-
ported by the strong positive relationships between the
clearance of creatinine and clearances of deconjugated
metanephrines.
Diagnosis of pheochromocytoma among patients with
ESRD is an important but difficult clinical challenge.
The importance of the diagnosis is underscored by con-
siderations that hypertension, and in particular, hemo-
dynamic instability and wild swings in blood pressure,
occur in both patients with renal failure and pheochro-
mocytoma. Moreover, some of the other varied signs
and symptoms that occur in patients with pheochromo-
cytoma, such as headaches, palpitations, and pulmonary
edema, can also be present in patients with renal failure.
Although pheochromocytomas are rare, numerous case
reports of the tumor in patients with renal failure fur-
ther attest to the importance of differential diagnosis of
the tumor among such patients [11, 18–25]. As reviewed
elsewhere [26], there are also numerous case reports of
coexistence of renal artery stenosis with pheochromocy-
toma. In some patients, not only the hypertension, but
also impaired renal function, may result from an undiag-
nosed tumor [18–20, 22]. Left untreated, such tumors are
invariably fatal, but once diagnosed are usually cured by
surgical resection.
Although important to diagnose, the possible associ-
ation of a pheochromocytoma with renal failure poses
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Fig. 3. Relationships between creatinine
clearance and plasma concentrations of
catecholamines, free metanephrines, or
deconjugated metanephrines in patients with
renal insufficiency () and VHL syndrome
().
a diagnostic dilemma, particularly acute in patients on
dialysis where traditional urinary tests of catecholamine
excess cannot be used. Increased sympathetic nervous
system activity in renal failure further compounds the dif-
ficulty of biochemical diagnosis by leading to increased
plasma concentrations of catecholamines [9, 10], this rep-
resenting the one remaining traditional biochemical test
for pheochromocytoma. In the present study, the high
proportion of renal failure patients with increased plasma
catecholamines illustrates the problem of using these an-
alytes for diagnostic purposes.
Another problem associated with diagnosis of
pheochromocytoma among patients with renal failure
results from the impaired renal clearance of alterna-
tive analytes that may be used for biochemical diagnosis
of the tumor. Serum levels of chromogranin A provide
one such alternative test for diagnosis of pheochromo-
cytoma. However, the circulatory clearance of chromo-
granin A depends on renal elimination, so that serum
levels of chromogranin A in patients with renal fail-
ure are increased well into the range usually observed
in patients with pheochromocytoma [27, 28]. Similarly,
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plasma levels of vanillylmandelic acid (VMA), a cat-
echolamine metabolite more commonly measured in
urine, are increased about 15-fold in patients with re-
nal failure compared to those with normal kidney func-
tion [29]. This is because as an end product of cate-
cholamine metabolism, clearance of VMA is entirely
dependent on renal elimination. As illustrated in the
present study, and in agreement with previous findings
[30, 31], this problem also occurs with measurements of
deconjugated metanephrines, which almost exclusively
reflect levels of sulfate-conjugated metabolites. Again,
as end products of catecholamine metabolism, sulfate-
conjugated metanephrines are cleared from the circula-
tion mainly, if not completely, by renal elimination in the
urine. Thus, like chromogranin A and VMA, measure-
ments of deconjugated metanephrines in plasma cannot
be used for diagnosis of pheochromocytoma among pa-
tients with renal failure and are also unreliable in those
with milder renal insufficiency states.
The kidneys make a 14% to 16% contribution to
the clearance of free metanephrines, and a 15% to
24% contribution to the clearance of circulating cat-
echolamines [3]. Thus, in contrast to the importance
of the kidneys for the clearance of VMA and sulfate-
conjugated metanephrines, the circulatory clearances of
free metanephrines and catecholamines are relatively
independent of renal function. Most circulating cate-
cholamines and free metanephrines are actively removed
from the circulation by non-neuronal monoamine trans-
porters in other tissues and organs where the amines
are subsequently metabolized before excretion [32]. Al-
though decreases in circulatory clearance resulting from
impaired renal function may contribute to increased
plasma concentrations of free normetanephrine and cat-
echolamines, these increases in patients with renal failure
probably mainly result from activation of the sympathetic
nervous system.
Previous studies have shown that normal plasma con-
centrations of free metanephrines are useful for exclud-
ing pheochromocytoma, but that occurrence of false-
positive results represents a remaining problem [7, 8].
False-positive results can be expected to be particularly
troublesome in patients with renal failure, where, as
shown here, 25% of patients had elevated plasma lev-
els of free metanephrines. However, judging the likeli-
hood of a pheochromocytoma from an initial positive
test result can benefit from consideration of the extent
of increase in the abnormal result [33]. In the present
series, no patient with renal failure had increases in
normetanephrine above 410 pg/mL or of metanephrine
above 142 pg/mL, and, as shown elsewhere, most patients
with pheochromocytoma have increases well above these
levels [7]. Thus, increases in plasma normetanephrine
above 410 pg/mL or of metanephrine above 142 pg/mL
are highly likely to indicate the tumor. Comparisons
with results for plasma catecholamines and responses
of plasma normetanephrine to clonidine provide other
methods for distinguishing true- from false-positive re-
sults [33]. Again, measurements must be accurate. This
can be a problem in patients with renal failure.
Accurate measurements of plasma free metanephrines
and catecholamines can be particularly troublesome in
patients on dialysis, where the circulatory accumulation
of blood-borne substances can interfere with biochem-
ical analyses. Apart from medications, our unpublished
observations indicate that such interferences can derive
from unknown constituents in the diet. In the patient with
ESRD on dialysis, dietary-derived substances are likely
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to accumulate independent of any fasting state. Possi-
bly, there may be less analytical interferences if blood
samples are obtained immediately after, and not be-
fore, dialysis. The period immediately after dialysis can
be, however, associated with hemodynamic instability,
which, through baroreflex-mediated sympathetic activa-
tion, may also compromise interpretation of biochemical
tests of catecholamine excess. Avoiding analytical prob-
lems may also be possible through improvements in sam-
ple extraction and purification procedures or use of new
analytical methods, such as liquid chromatography with
tandem mass spectroscopy [34]. The latter recently devel-
oped method offers improved analytical specificity that
might be particularly suitable for patients with renal fail-
ure.
CONCLUSION
Plasma concentrations of free metanephrines are rel-
atively independent of renal function and, therefore,
along with measurements of plasma catecholamines, of-
fer a suitable test for diagnosis of pheochromocytoma
in patients with renal failure. Because of the previously
published higher diagnostic sensitivity of plasma free
metanephrines than catecholamines [5–8], we recom-
mend that the decision to exclude pheochromocytoma
should be based primarily on normal results for plasma
free metanephrines. Where plasma free metanephrines
are elevated, clinicians should be sensitive to the possi-
bility of false-positive results due to influences of sym-
pathetic activation and unrecognized analytical interfer-
ences. Due to the latter possibility, consideration should
be given to corroboration of positive tests results by re-
peated testing of plasma free metanephrines, perhaps
best achieved using a different testing laboratory and
method of analysis.
Reprint requests to Graeme Eisenhofer, Building 10, Room 6N252,
National Institutes of Health, 10 CENTER DR, MSC-1620, Bethesda,
MD 20892–1620.
E-mail: ge@box-g.nih.gov
REFERENCES
1. KOPIN IJ: Catecholamine metabolism: Basic aspects and clinical sig-
nificance. Pharmacol Rev 37:333–364, 1985
2. EISENHOFER G, FRIBERG P, PACAK K, et al: Plasma metadrenalines:
Do they provide useful information about sympatho-adrenal func-
tion and catecholamine metabolism? Clin Sci (Lond) 88:533–542,
1995
3. EISENHOFER G, RUNDQUIST B, ANEMAN A, et al: Regional release
and removal of catecholamines and extraneuronal metabolism to
metanephrines. J Clin Endocrinol Metab 80:3009–3017, 1995
4. EISENHOFER G, HUYNH TT, HIROI M, PACAK K: Understanding cat-
echolamine metabolism as a guide to the biochemical diagnosis of
pheochromocytoma. Rev Endocr Metab Disord 2:297–311, 2001
5. EISENHOFER G, LENDERS JW, LINEHAN WM, et al: Plasma
normetanephrine and metanephrine for detecting pheochromocy-
toma in von Hippel-Lindau disease and multiple endocrine neopla-
sia type 2. N Engl J Med 340:1872–1879, 1999
6. RABER W, RAFFESBERG W, BISCHOF M, et al: Diagnostic efficacy of
unconjugated plasma metanephrines for the detection of pheochro-
mocytoma. Arch Intern Med 160:2957–2963, 2000
7. LENDERS JW, PACAK K, WALTHER MM, et al: Biochemical diagnosis
of pheochromocytoma: Which test is best? JAMA 287:1427–1434,
2002
8. SAWKA AM, JAESCHKE R, SINGH RJ, YOUNG WF, JR.: A compari-
son of biochemical tests for pheochromocytoma: Measurement of
fractionated plasma metanephrines compared with the combina-
tion of 24-hour urinary metanephrines and catecholamines. J Clin
Endocrinol Metab 88:553–558, 2003
9. CONVERSE RL, JR., JACOBSEN TN, TOTO RD, et al: Sympathetic
overactivity in patients with chronic renal failure. N Engl J Med
327:1912–1918, 1992
10. NEUMANN J, LIGTENBERG G, KLEIN II, et al: Sympathetic hyperactiv-
ity in chronic kidney disease: Pathogenesis, clinical relevance, and
treatment. Kidney Int 65:1568–1576, 2004
11. STUMVOLL M, RADJAIPOUR M, SEIF F: Diagnostic considerations in
pheochromocytoma and chronic hemodialysis: Case report and re-
view of the literature. Am J Nephrol 15:147–151, 1995
12. LAEDERACH K, WEIDMANN P: Plasma and urinary catecholamines as
related to renal function in man. Kidney Int 31:107–111, 1987
13. ROBERTS NB, DUTTON J, MCCLELLAND Bone JM: Urinary cate-
cholamine excretion in relation to renal function. Ann Clin Biochem
36 (Pt 5):587–591, 1999
14. LENDERS JW, EISENHOFER G, ARMANDO I, et al: Determination of
metanephrines in plasma by liquid chromatography with electro-
chemical detection. Clin Chem 39:97–103, 1993
15. EISENHOFER G, GOLDSTEIN DS, STULL R, et al: Simultaneous liquid-
chromatographic determination of 3,4-dihydroxyphenylglycol, cat-
echolamines, and 3,4-dihydroxyphenylalanine in plasma, and their
responses to inhibition of monoamine oxidase. Clin Chem 32:2030–
2033, 1986
16. WILLEMSEN JJ, ROSS HA, WOLTHERS BG, et al: Evaluation of spe-
cific high-performance liquid-chromatographic determinations of
urinary metanephrine and normetanephrine by comparison with
isotope dilution mass spectrometry. Ann Clin Biochem 38:722–730,
2001
17. EISENHOFER G, LENDERS JW, PACAK K: Biochemical diagnosis of
pheochromocytoma. Front Horm Res 31:76–106, 2004
18. TAKABATAKE T, KAWABATA M, OHTA H, et al: Acute renal failure
and transient, massive proteinuria in a case of pheochromocytoma.
Clin Nephrol 24:47–49, 1985
19. RAMAN GV: Phaeochromocytoma presenting with cardiogenic
shock and acute renal failure. J Hum Hypertens 1:237–238, 1987
20. SHEMIN D, COHN PS, ZIPIN SB: Pheochromocytoma presenting as
rhabdomyolysis and acute myoglobinuric renal failure. Arch Intern
Med 150:2384–2385, 1990
21. YVER L, JAULIN JP, NANHUCK H, RIVET P: Pheochromocytoma in a
long-term hemodialysis patient. Am J Kidney Dis 18:276–277, 1991
22. HAMADA N, AKAMATSU A, JOH T: A case of pheochromocytoma
complicated with acute renal failure and cardiomyopathy. Jpn Circ
J 57:84–90, 1993
23. BOX JC, BRAITHWAITE MD, DUNCAN T, LUCAS G: Pheochromocy-
toma, chronic renal insufficiency, and hemodialysis: A combination
leading to a diagnostic and therapeutic dilemma. Am Surg 63:314–
316, 1997
24. GODFREY JA, RICKMAN OB, WILLIAMS AW, et al: Pheochromocy-
toma in a patient with end-stage renal disease. Mayo Clin Proc
76:953–957, 2001
25. MORIOKA M, YUIHAMA S, NAKAJIMA T, et al: Incidentally discovered
pheochromocytoma in long-term hemodialysis patients. Int J Urol
9:700–703, 2002
26. HILL FS, JANDER HP, MURAD T, DIETHELM AG: The coexistence of
renal artery stenosis and pheochromocytoma. Ann Surg 197:484–
490, 1983
27. HSIAO RJ, MEZGER MS, O’CONNOR DT: Chromogranin A in ure-
mia: Progressive retention of immunoreactive fragments. Kidney
Int 37:955–964, 1990
28. TRAMONTI G, FERDEGHINI M, ANNICHIARICO C, et al: Relationship
between renal function and blood level of chromogranin A. Ren
Fail 23:449–457, 2001
29. HOELDTKE RD, ISRAEL BC, CAVANAUGH ST, KRISHNA GG: Effect
Eisenhofer et al: Metanephrines and renal failure 677
of renal failure on plasma dihydroxyphenylglycol, 3-methoxy-4-
hydroxyphenylglycol, and vanillymandelic acid. Clin Chim Acta
184:195–196, 1989
30. MORNEX R, PEYRIN L, PAGLIARI R, COTTET-EMARD JM: Measure-
ment of plasma methoxyamines for the diagnosis of pheochromo-
cytoma. Horm Res 36:220–226, 1991
31. MARINI M, FATHI M, VALLOTTON M: Determination of serum
metanephrines in the diagnosis of pheochromocytoma. Ann En-
docrinol (Paris) 54:337–342, 1994
32. EISENHOFER G: The role of neuronal and extraneuronal plasma
membrane transporters in the inactivation of peripheral cate-
cholamines. Pharmacol Ther 91:35–62, 2001
33. EISENHOFER G, GOLDSTEIN DS, WLATHER MM, et al: Biochemical
diagnosis of pheochromocytoma: How to distinguish true- from
false-positive test results. J Clin Endocrinol Metab 88:2656–2666,
2003
34. LAGERSTEDT SA, O’KANE DJ, SINGH RJ: Measurement of
plasma free metanephrine and normetanephrine by liquid
chromatography-tandem mass spectrometry for diagnosis of
pheochromocytoma. Clin Chem 50:603–611, 2004
